The more Hanmi Pharmaceutical’s new drugs sell, the more Hanmi Science benefits... Hopes for higher patent revenue
- Input
- 2026-11-09 09:00:25
- Updated
- 2026-11-09 09:00:25

[Financial News] Hanmi Science is expected to benefit from improved profitability as Hanmi Pharmaceutical commercializes new drugs and expands global technology exports, according to brokerage analysts. As the link between new-drug development achievements and patent allocation income and business-contribution income from technology exports comes into focus, attention is also turning to the possibility of a revaluation of the holding company.
On the 9th, Lee Sang-heon, an analyst at iM Securities, forecast that “increases in patent allocation income as commercialization advances and expanded technology exports will accelerate improvements in profitability” at Hanmi Science. However, he did not issue an investment rating or a target price.
The key point is its earnings structure. Hanmi Science secured numerous original technologies and patents during its transition to a holding-company structure in 2010. As a result, Hanmi Pharmaceutical’s new-drug commercialization and global technology-transfer achievements translate into income for the holding company in proportion to its contributions in technology and patents.
A leading example is efpeglenatide, a treatment for obesity and metabolic diseases. Hanmi Pharmaceutical received marketing approval on October 7, and the drug began to be prescribed at some medical institutions on the 29th of the same month. If sales expand on the strength of its domestic manufacturing base and competitive pricing, Hanmi Science’s patent allocation income is also expected to rise.
iM Securities also viewed progress in clinical trials for the global new-drug pipeline positively. The analyst said, “Efinopegdutide, which Hanmi Pharmaceutical licensed to U.S.-based MSD in 2020 in a deal worth up to $870 million, recently achieved meaningful results in a Phase 2b trial for metabolic dysfunction-associated steatohepatitis (MetALD).”
According to results MSD presented on the 6th at the American Association for the Study of Liver Diseases, the MetALD resolution rate was significantly higher than with placebo, and the 7 mg dose group also showed a statistically significant improvement in liver fibrosis. Whether the drug advances to Phase 3 trials is seen as a factor that will affect medium- to long-term revenue growth.
The growing role of the holding company in technology-export deals is also worth noting. Hanmi Science took a leading role in the technology-transfer agreement for HM17321, an obesity drug candidate, which Hanmi Pharmaceutical signed in August with Genentech, a Roche Group subsidiary. The deal is expected to increase business-contribution income.
Expansion of its own businesses is another growth driver. Hanmi Science is strengthening its business-to-consumer (B2C) operations through brands including Adesi, a cosmetics brand; Caremi, a nutrition-care brand; and Enple, a health-functional-food brand.
The analyst emphasized, “Hanmi Science is strengthening its role as an intellectual property (IP)-based revenue-generating platform and as the control tower for its new-drug business,” adding, “Growth in patent allocation income and business-contribution income will lead to sales growth and improved profitability.”
[email protected] Kim Gyeong-a Reporter